Clario provides clinical evidence generation services and technologies to pharmaceutical, biotechnology, and medical device companies. The company operates across the full spectrum of clinical trial needs, from endpoint measurement and cardiac safety assessment to electronic clinical outcome collection and medical imaging services. Its platform supports decentralized, hybrid, and traditional site-based trial models, underpinned by cloud-native and AI-powered technologies.
The company's scale reflects decades of embedded expertise in clinical research. It has supported nearly 900 regulatory approvals across 19,000 studies spanning almost 600 indications, drawing on over 50 years of organisational experience. Clario maintains a presence in more than 80,000 clinical trial sites worldwide, positioning it to manage both the technical and logistical complexity of modern drug development.
Clario's endpoint technology platform integrates solutions for cardiac safety, respiratory endpoints, precision motion capture, and clinical adjudication - capabilities designed to reduce trial risk and accelerate the path from development to approval. The company combines deep scientific knowledge with modern infrastructure to address the operational challenges that pharmaceutical and biotech organisations face in generating high-quality clinical evidence.
